VERALIGHT (SCOUT STUDY)
Principal Investigator: Patricia A. Cleary, M.S.
This study involves a study of the device, SCOUT DS System, that employs fluorescence spectroscopy to non-invasively measure advanced glycation endproducts (AGEs) in the skin of an individual's forearm as an indicator of cumulative hyperglycemic exposure shown to predict the development of type 2 diabetes. AGEs are macroprotein complexes formed by the Maillard reaction of reducing sugars with free amino groups on proteins, amino acids, or lipids. Although they increase naturally with age, their formation is accelerated with chronic hyperglycemia and oxidative stress. AGEs are associated with almost all long-term complications of diabetes, and increased levels have been observed in the collagen of those with diabetes. In the Diabetes Control and Complications Trial, AGEs were a better marker of progression to micro-vascular complications than was A1C (Monnier et al., 1999). Several AGEs form fluorescent molecular cross-links. Increased fluorescence has been observed in the skin, retina, and kidney of individuals with diabetes (Forbes et al., 2005)Conventional AGE assays require a skin biopsy and are time intensive. Skin fluorescence provides a summary measure of skin AGEs and may be a strong indicator of diabetes complications. Funded through a subagreement with the VeraLight Corporation, 2009-2012.)